In an exclusive interview, Hims & Hers CEO Andrew Dudum defended the company's practices amid a lawsuit from the Federal Trade Commission, which claims the company improperly shared user health information with advertisers and made it difficult for customers to cancel subscriptions.
Dudum argued that the lawsuit reflects a misunderstanding of how Hims & Hers is transforming healthcare through digital solutions. He emphasized the company's commitment to increasing access to care and described their transition from compounded to branded GLP-1 drugs, which followed a patent infringement lawsuit from Novo Nordisk that was later dropped.
Dudum anticipates that prices for cash-paying patients for these medications could decrease significantly, from $150-$200 to around $40-$50 per month. Additionally, he expressed confidence in the transformative potential of artificial intelligence in healthcare, stating that Hims & Hers is focusing on developing its own AI capabilities rather than relying on third-party solutions.
This strategic shift could enhance the company's competitive edge in the evolving telehealth market